Special Focus Review

Sebaceous gland receptors

Christos C. Zouboulis

Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Dessau, Germany; Laboratory of Biogerontology; Dermato-Pharmacology and Dermato-Endocrinology; Institute of Clinical Pharmacology and Toxicology; Charité Universitaetsmedizin Berlin; Berlin, Germany

Key words: sebaceous gland, sebocytes, skin, human, receptor, hormone

Receptors are proteins, embedded in a cell or cytoplasmic membrane, to which a mobile signaling molecule may attach. Receptor ligands may be peptides (such as neurotransmitters), hormones, pharmaceutical drugs and/or a toxins, whereas "binding" ordinarily initiates a cellular response. Human sebocytes are biologically and metabolically very active cells and consequently express numerous receptors. Three of four groups of peptide/neurotransmitter receptors, the so-called serpentine receptor group are present (corticotropin-releasing hormone receptors 1 and 2, melanocortin-1 and 5 receptors, µ-opiate receptors, VPAC receptors, cannabinoid receptors 1 and 2, vascular endothelial growth factor receptor and histamine 1 receptor). The single-transmembrane domain receptors are represented by the insulin-like growth factor-I receptor and the third group, which does not possess intrinsic tyrosine kinase activity, by the growth factor receptor. Nuclear receptors expressed in sebocytes are grouped into two major subtypes. From the steroid receptor family, the androgen receptor and the progesterone receptor are expressed. The thyroid receptor family includes the estrogen receptors (α and β isotypes), the retinoic acid receptors (isotypes α and γ) and retinoid X receptors (isotypes α , β , γ), the vitamin D receptor, the peroxisome proliferator-activated receptors (isotypes α , δ and γ) and the liver X receptors (α and β isotypes). The vanilloid receptor belongs to the transient ion channels and is expressed in differentiating human sebocytes. Further sebocyte receptors, which may influence their function are fibroblast growth factor receptor 2, epidermal growth factor receptor, c-MET, CD14, Toll-like receptor 2, Toll-like receptor 4 and Toll-like receptor 6. Receptor-ligand interactions control sebocyte proliferation, differentiation and lipid synthesis. However, not every ligand that binds to a sebocyte receptor also activates it, such ligands are receptor antagonists and inverse agonists.

Introduction

Sebocytes, also called sebaceous gland cells, form the sebaceous gland, a holocrine gland of the skin composed of acini attached

Correspondence to: Christos C. Zouboulis; Departments of Dermatology, Venereology, Allergology and Immunology; Dessau Medical Center; Auenweg 38; Dessau 06847 Germany; Tel.: +49.340.5014000; Fax: +49.340.5014025; Email: christos. zouboulis@klinikum-dessau.de

Submitted: 01/06/09; Accepted: 01/08/09

Previously published online as a *Dermato-Endocrinology* E-publication: http://www.landesbioscience.com/journals/dermatoendocrinology/article/7804

to a common excretory duct. These glands are found throughout the skin except on the palms and soles. They are highly hormonesensitive and account for the vast majority of hormone metabolism in the skin.

Sebocytes are epithelial cells that originate from a basal cell layer at the periphery of the gland. Differentiation and maturation of sebocytes is accompanied by the accumulation of increasing amounts of a unique mixture of lipids (sebum). Approximately 25% of human sebaceous lipids are wax esters that are not synthesized by other cells in the body. With respect to lipogenesis sebocyte differentiation may follow a similar program of differentiation as that observed in adipocytes. These lipid-laden cells then migrate towards the central excretory duct. Eventually, the cells disintegrate and release their lipid content in a holocrine manner. Most of the lipids of the skin surface (approx. 90%) originate from sebaceous glands secretions.

Many studies on human sebocytes have been performed with SZ95 cells, an immortalized human sebaceous gland cell line that shows the morphologic, phenotypic and functional characteristics of normal human sebocytes.^{3,4} Makrantonaki and Zouboulis⁵ have described the expression profile of human SZ95 sebocytes that are differentially expressed in an age-related manner.

Human sebocytes express, among others, receptors for peptide hormones, neurotransmitters, which are mostly arranged on the cell surface, and for steroid and thyroid hormones, which are found in the cytoplasm or nuclear compartment.^{4,6}

Sebocyte Receptors

Peptide hormone and neurotransmitter receptors. (Table 1) Three of four groups of peptide hormone and neurotransmitter receptors are represented in human sebocytes. To the first so-called serpentine or "seven transmembrane domain" receptor group belong

- Corticotropin-releasing hormone (CRH) receptor (CRH-R)1 and 2, whereas CRH-R1 is more abundant and seems to regulate CRH activity. Through binding to CRH-R1, CRH and urocortin reduce sebocyte proliferation. CRH upregulates Δ^{5-4} 3 β -hyroxysteroid dehydrogenase expression, synthesis of neutral lipids and interleukin (IL)6 and IL8 release;
- Melanocortin (α -melanocyte stimulating hormone, α -melanocortin, α -melanotropin, melanotropin)-1 and 5 receptors (MC-1R and MC-5R), which bind α -melanocyte stimulating hormone and are located at the cellular surface of sebocytes. MC-1R regulates inflammation in SZ95 sebocytes and exhibits a stronger expression in acne-involved sebaceous glands. The expression of MC-5R is

Table 1 Sebaceous gland receptors and their functions on human sebocytes

| Receptor | Ligand | Proliferation | Differentiation/ Apoptosis | Lipid synthesis | Cytokine synthesis |
|---------------------------|---|---------------|-------------------------------|--------------------|--------------------|
| Peptide Hormone Receptors | | | | • | • |
| CRHR1 | CRH, urocortin | \downarrow | | \uparrow | \uparrow |
| CRHR2 | | | | | |
| MC-1R | α-MSH | \downarrow | | | |
| MC-5R | α-MSH | | \uparrow | | |
| OPR | β-endorphin | | | \uparrow | |
| VPAC | VIP, NY, CGRP | | | | \uparrow |
| CBR1 | | | \uparrow | | |
| CBR2 | Endocannabinoids | | \downarrow | | |
| Histamine-1R | Histamine, antihistaminics | | | ↓ (squalene) | |
| IGF-IR | IGF-I, insulin | | | \uparrow | |
| GHR | GH | | | \uparrow | |
| Nuclear Receptors | | | | | |
| AR | Androgens | \uparrow | | \leftrightarrow | |
| PR | Progesterone | | | | |
| ER-α | Estrogens | | | | |
| ER-β | Estrogens | | | ↑ (polar lipids) | |
| $RAR\alpha$ | Tretinoin | \downarrow | | | |
| RARγ | Tretinoin | \downarrow | | | |
| $RXR\alpha$ | Retinoids | \uparrow | \uparrow | | |
| RXRβ | | | | | |
| RXRγ | | | | | |
| VDR | Vit. D Do not distribu | rte.↑ | \downarrow | \downarrow | |
| $PPAR\alpha$ | LTB4 | | | \downarrow | \uparrow |
| PPARγ | Linoleic acid, 15d-PGJ2, thioglitazones, WY 14643 | | | \uparrow | |
| LXR-α | 22(R)-hydroxycholesterol, TO901317 | \downarrow | | \uparrow | |
| LXR-β | | | | | |
| VR | Capsaicin | \downarrow | | | |
| Other Receptors | | | | | |
| FGFR2b | | | | | |
| EGF | HGF | | | | |
| c-MET | | | | | |
| CD14 | | | | | \uparrow |
| TLR-2 | LPS | | | | \uparrow |
| TLR-4 | LTA | | | | \uparrow |
| TLR-6 | | | | | \uparrow |

weaker than that of MC1-R but has been shown to be a marker of human sebocyte differentiation, since it is expressed in differentiated, lipid-containing sebocytres, only.¹¹

- μ -opiate receptors (OPR), which bind β -endorphin. β -Endorphin stimulates lipogenesis and specifically increases the amount of C16:0, C16:1, C18:0, C18:1 and C18:2 fatty acids to an extent similar to linoleic acid in sebocytes. ¹²
- VPAC receptors, which bind vasoactive intestinal popypeptide (VIP), neuropeptide Y (NY) and calcitonin gene-related peptide (CGRP). ¹³ NY activates cytokine synthesis. CGRP is often co-localized with substance P. ¹⁴
- Cannabinoid receptors (CBR) 1 and 2 are expressed in SZ95 sebocytes and sebaceous glands. 14,15 CBR1 was found in the

differentiated sebocytes and CBR2 in the undifferentiated cells, whereas endocannabinoids influence sebocyte differentiation via CBR2.

• Histamine 1 receptor, which is bound by histamine and regulates squalene synthesis. ¹⁶ Antihistaminics, ligands of histamine 1 receptor reduced squalene synthesis in SZ95 sebocytes.

The insulin-like growth factor (IGF)-I receptor belongs to the second group, the single-transmembrane domain receptors, that harbor intrinsic tyrosine kinase activity, is expressed on SZ95 sebocyte cell surface and can be activated by IGF-I and high concentrations of insulin. ¹⁷ IGF-I amplifies lipid accumulation in SZ95 sebocytes in a dose dependent manner. The activation of the IGF-I receptor induced lipogenesis in SEB-1 sebocytes by sterol response

element-binding protein-dependent and independent pathways. ¹⁸ IGF-I also stimulates proliferation and differentiation of rat preputial gland cells, which resemble sebocytes, especially in combination with growth hormone (GH). ¹⁹

The third group, which is functionally similar to the second group, does not possess intrinsic tyrosine kinase activity but appear to function through interaction with soluble transducer molecules which do possess such activity. In human sebocytes, they are represented by the GH receptor, whose regulation by GH upregulates sebocyte differentiation and augments the effect of 5α -dihydrotestosterone (DHT) on sebum synthesis. ¹⁹

Nuclear receptors. The nuclear receptors are soluble molecules and employ transcriptional regulation as a means of promoting their biological effects. Thus, though some receptors are compartmentalized in the cytoplasm while others are defined to the nucleus, they all operate within the nuclear chromatin where they bind a hormone-specific "hormone response element". These receptors are expressed in human sebocytes and can be grouped into two major subtypes based on shared structural and functional properties.

From the first group, the steroid receptor family, the androgen receptor (AR) and the progesterone receptor (PR) are present in human sebocytes, in basal and early differentiated ones. 6,20,21

- AR is stabilized und upregulated by ligand binding, its downregulation reduces sebocyte proliferation. ²² Five intracellular enzymes—all of them expressed in sebocytes ²⁰—are involved in activation—before binding to AR—and inactivation of androgens. DHEA-sulfate is metabolized by the stearoyl CoA desaturase to DHEA. DHEA and androstosterone are converted to testosterone and later to DHT by 5α-reductase. ^{20,23} Sebocyte studies of Akamatsu et al. and Zouboulis et al. showed a dose dependent induction of sebocyte proliferation by testosterone treatment ²⁴ and no effect on lipid stimulation. ³ Investigations by Rosenfield et al. and Makrantonaki et al. proved that the expected effect of androgens on sebaceous lipids is mediated by peroxisome proliferators-activated receptor (PPAR) ligands. ^{25,26}
- Progesterone receptor (PR) was found in nuclei of basal sebocytes of sebaceous glands. ^{21,27}

From the second group, the thyroid receptor family, the following receptors are expressed in human sebocytes:

- Estrogen receptors (ER; α and β -isotypes). ²⁷⁻²⁹ ER- β is expressed in basal and partially differentiated sebocytes. ER- α is expressed in basal and early differentiated sebocytes. One of the natural estrogens, estradiol, is created by oxidative reduction of 4-androsten-3, 17-dion, like testosterone. Treatment of sebocytes with 17 β -estradiol showed an effect on polar lipid production but no stimulating effect on neutral lipids. ³⁰ Other previous in vitro data indicated that estrogens may have an influence on the biological activity of sebaceous glands. ³¹
- Retinoic acid receptors (RAR; isotypes α and γ) and retinoid X receptors (RXR; isotypes α , β , γ). ^{32,33} RAR α and γ and RXR α are the predominant retinoid receptors in human sebocytes, RAR regulate cell proliferation. ³³ The natural ligands for RAR and RXR are atRA and 9-cis retinoic acid. 13-cis retinoic acid (13cRA) inhibits proliferation in SZ95 sebocytes, whereas 13cRA was found to be metabolized intracellularly to the RAR ligand atRA. RXR agonists are stimulating sebocyte differentiation and proliferation. The RXR agonists rexinoids in combination with the specific PPAR agonists,

WY 14643, troglitazone and cabaprostacyclin affected differentiation and growth in cultured primary sebocyte-like rat preputial cells.³⁴

- Vitamin D receptor (VDR). SZ95 sebocytes also express vitamin D-25-hydroxylase (25OHase), 25-hydroxyvitamin D-1 α -hydroxylase (1 α OHase) and 1,25-dihydroxyvitamin D-24-hydroxylase (24OHase). Induces time- and dose-dependent modulation of cell proliferation, cell cycle regulation, lipid content and IL6 and IL8 secretion by cultured sebocytes. RNA expression of VDR and 24OHase was upregulated along with vit. D3 treatment.
- Peroxisome proliferators-activated receptors (PPAR; α , δ and γ isotypes). ^{25,37,38} PPAR α and γ are the predominant PPAR subtypes in human sebocytes. PPAR are present in mitochondria, peroxisomes and microsomes of sebocytes and regulate multiple lipid metabolic genes.
- Liver X receptors (LXR, α and β isotypes). ^{39,40} SZ95 sebocytes express both receptors at the mRNA and protein levels. The application of natural 22(R)-hydroxycholesterol or synthetic ligands significantly inhibited proliferation and increased lipogenesis. The expression of known LXR targets, such as fatty acid synthase and SREBP1, was induced by the synthetic LXR ligand TO901317, which also decreased the expression of cyclooxygenase 2 and inducible nitric oxide synthase that was induced by lipopolysaccharide treatment. ⁴⁰

The vanilloid receptor (VR) belongs to the transient ion channels and is expressed in differentiating sebocytes.⁴¹ VR ligand capsaicin was shown to reduce SZ95 sebocyte proliferation.

Other receptors. Other receptors been identified in human sebocytes are

- family of related but individually distinct tyrosine kinase receptors. Four FGFRs designated FGFR1 to FGFR4 have been identified, two splice variants of FGFR2 are designated FGFR2b and FGFR2c. FGFR2b is localized mainly in the suprabasal spinous layer of the epidermis and sebocytes and plays a crucial role in controlling epithelial proliferation and differentiation. Increased fibroblast growth factor receptor-2 (FGFR2) signaling has been proposed to be involved in the pathogenesis of acne and explains acne in Apert syndrome and unilateral acneiform nevus associated with gain-of-function point mutations of FGFR2. 42
- Epidermal growth factor (human milk growth factor, prostatic growth factor, β -urogastrone, urogastrone) receptor.⁴³
- the proto-oncogene c-met product (c-MET), which is a receptor tyrosine kinase and functions as a receptor for hepatocyte growth factor (HGF; hepatocyte growth factor-scatter factor, fibroblast tumor cytotoxic factor, hepatopoietin A, scatter factor, tumor cytotoxic factor). 44
- CD14 (endotoxin receptor, Leu M3, LPS-R, Mo2, MY4, myeloid cell-specific leucine-rich glycoprotein), Toll-like receptor (TLR)-2 (Toll-interleukin-1 receptor-like-4, lymphocyte antigen 105, CD282), TLR-4 (lymphocyte antigen 87, Rasl2-8, CD284) and TLR-6 (CD286), which indicate that human sebocytes are immunologically active cells capable of TLR- and CD14-mediated bacterial recognition and play an important role in initiating and perpetuating the activation of both innate and adaptive immune responses. 45,46

References

- 1. Zouboulis CC. Acne and sebaceous gland function. Clin Dermatol 2004; 22:360-6.
- Harrison WJ, Bull JJ, Seltmann H, Zouboulis CC, Philpott MP. Expression of lipogenic factors galectin-12, resistin, SREBP-1 and SCD in human sebaceous glands and cultured sebocytes. J Invest Dermatol 2007; 127:1309-17.
- Zouboulis CC, Seltmann H, Neitzel H, Orfanos CE. Establishment and characterization of an immortalized human sebaceous gland cell line (SZ95). J Invest Dermatol 1999; 113:1011-20.
- Zouboulis CC, Schagen S, Alestas T. The sebocyte culture—A model to study the pathophysiology of the sebaceous gland in sebostasis, seborrhoea and acne. Arch Dermatol Res 2008; 300:397-413.
- Makrantonaki E, Zouboulis CC. The skin as a mirror of the aging process in the human organism—State of the art and results of the aging research in the German National Genome Research Network 2 (NGFN-2). Experimental Gerontology 2007; 42:879-86.
- Zouboulis CC. The human skin as a hormone target and an endocrine gland. Hormones 2004; 3:9-26.
- Krause K, Schnitger A, Fimmel S, Glass E, Zouboulis CC. Corticotropin-releasing hormone skin signalling is receptor-mediated and is predominant in the sebaceous glands. Horm Metab Res 2007; 39:166-70.
- Zouboulis CC, Seltmann H, Hiroi N, Chen W, Young M, Oeff M, et al. Corticotropin releasing hormone: An autocrine hormone that promotes lipogenesis in human sebocytes. Proc Natl Acad Sci USA 2002; 99:7148-53.
- Böhm M, Schiller M, Ständer S, Seltmann H, Li Z, Brzoska T, et al. Evidence for expression of melanocortin-1 receptor in human sebocytes in vitro and in situ. J Invest Dermatol 2002; 118:533-9.
- Ganceviciene R, Graziene V, Böhm M, Zouboulis CC. Increased in situ expression of melanocortin-1 receptor in sebaceous glands of lesional skin of patients with acne vulgaris. Exp Dermatol 2007; 16:547-52.
- Zhang L, Li W, Anthonavage M, Eisinger M. Melanocortin-5 receptor: A marker of human sebocyte differentiation. Peptides 2006; 27:413-20.
- Böhm M, Li Z, Ottaviani M, Picardo M, Zouboulis CC, Ständer S, et al. Beta-endorphin modulates lipogenesis in human sebocytes. J Invest Dermatol 2004; 123:10.
- Seiffert K, Zouboulis CC, Seltmann H, Granstein R. Expression of neuropeptide receptors by human sebocytes and stimulatory effect of their agonists on cytokine production. Horm Res 2000; 53:102.
- Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005; 38:177-88.
- Dobrosi N, Tóth B, Nagy G, Dózsa A, Géczy T, Nagy L, et al. Endocannabinoids enhance lipid synthesis in human sebocytes via cannabinoid receptor-2-mediated signaling. FASEB J 2008; 22:3685-95.
- Pelle E, McCarthy J, Seltmann H, Huang X, Mammone T, Zouboulis CC, et al. Identification of histamine receptors and reduction of squalene levels by an antihistamine in sebocytes. J Invest Dermatol 2008; 128:1280-5.
- Makrantonaki E, Adjaye J, Herwig R, Brink T, Groth D, Hultschig C, et al. Age-specific hormonal decline is accompanied by transcriptional changes in human sebocytes in vitro. Aging Cell 2006; 5:331-44.
- Smith T, Cong Z, Gilliland K, Clawson G, Thiboutot D. Insulin-like growth factor-1 induces lipid production in human SEB-1 sebocytes via sterol response element-binding protein-1. J Invest Dermatol 2006; 126:1226-32.
- Deplewski D, Rosenfield R. Growth hormone and insulin like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology 1999; 140:4089-94.
- Fritsch M, Orfanos C, Zouboulis CC. Sebocytes are the key regulators of androgen homeostasis in human skin. J Invest Dermatol 2001; 116:793-800.
- Zouboulis CC, Chen W, Thornton M, Qin K, Rosenfield R. Sexual hormones in human skin. Horm Metab Res 2007; 39:85-95.
- Fimmel S, Saborowski A, Térouanne B, Sultan C, Zouboulis CC. Inhibition of the androgen receptor by antisense oligonucleotides regulates the biological activity of androgens in SZ95 sebocytes. Horm Metab Res 2007; 39:149-56.
- Chen W, Zouboulis CC, Fritsch M, Blume-Peytavi U, Kodelja V, Goerdt S, et al. Evidence
 of heterogeneity and quantitative differences of the type 1 5α-reductase expression in cultured human skin cells. Evidence of its presence in melanocytes. J Invest Dermatol 1998;
 110:84-9.
- Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5α-dihydrotestosterone in vitro. J Invest Dermatol 1993; 100:660-2.
- Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5α-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferators-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol 2007; 156:428-32.
- Rosenfield R, Deplewski D, Kentsis A, Ciletti N. Mechanisms of androgen induction of sebocyte differentiation. Dermatology 1998; 196:43-6.
- Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol Histopathol 2004; 19:629-36.

- Thornton M, Nelson L, Taylor AH, Birch M, Laing I, Messenger A. The modulation of aromatase and estrogen receptor α in cultured human dermal papilla cells by dexamethasone: A novel mechanism for selective action of estrogen via estrogen receptor beta? J Invest Dermatol 2006; 126:2010-8.
- Thornton M, Taylor A, Mulligan K, Al-Azzawi F, Lyon C, O'Driscoll J, et al. Oestrogen receptor-β is the predominant oestrogen receptor in human scalp skin. Exp Dermatol 2003; 12:181-90.
- Makrantonaki E, Vogel K, Fimmel S, Oeff M, Seltmann H, Zouboulis CC. Interplay of IGF-I and 17β-estradiol at age-specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol 2008; 43:939-46.
- 31. Guy R, Green M, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106:176-82.
- Reichrath J, Mittmann M, Kamradt J, Müller S. Expression of retinoid-X receptors (-α, -β, -γ) and retinoic acid receptors (-α, -β, -γ) in normal human skin: An immunohistological evaluation. Histochem J 1997; 29:127-33.
- 33. Tsukada M, Schroder M, Roos T, Chandraratna R, Reichert U, Merk H, et al. 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol 2000; 115:321-7.
- 34. Kim M, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield R. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol Genet Metab 2001; 74:362-9.
- Reichrath J, Classen U, Meineke V, DeLuca H, Tilgen W, Kerber A, et al. Immunoreactivity
 of six monoclonal antibodies directed against 1,25-dihydroxyvitamin-D3 receptors in
 human skin. Histochem J 2000; 32:625-9.
- Krämer C, Seltmann H, Seifert M, Tilgen W, Zouboulis CC, Reichrath J. Characterization of the vitamin D endocrine system in human sebocytes in vitro. J Steroid Biochem Mol Biol 2009; 113:9-16.
- Alestas T, Ganceviciene R, Fimmel S, Müller-Decker K, Zouboulis CC. Enzymes involved in the biosynthesis of leukotriene B₄ and prostaglandin E₂ are active in sebaceous glands. J Mol Med 2006; 84:75-87.
- 38. Schmuth M, Ortegon A, Mao-Qiang M, Elias P, Feingold K, Stahl A. Differential expression of fatty acid transport proteins in epidermis and skin appendages. J Invest Dermatol 2005; 125:1174-81.
- Russell L, Harrison W, Bahta A, Zouboulis CC, Burrin J, Philpott M. Characterization of liver X receptor expression and function in human skin and the pilosebaceous unit. Exp Dermatol 2007; 16:844-52.
- 40. Hong I, Lee M, Na T, Zouboulis CC, Lee M. LXRα enhances lipid synthesis in SZ95 sebocytes. J Invest Dermatol 2008; 128:1266-72.
- 41. Tóth BI, Géczy T, Griger Z, Dózsa A, Seltmann H, Kovács L, Nagy L, Zouboulis CC, Paus R, Bíró T. Transient receptor potential vanilloid-1 signaling as a regulator of human sebocyte biology. J Invest Dermatol 2008; [Epub ahead of print].
- 42. Melnik B, Schmitz G, Zouboulis CC. Anti-acne agents attenuate FGFR2 signal transduction in acne. J Invest Dermatol, in press.
- Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385-93.
- 44. Saitoh K, Takahashi H, Sawada N, Parsons PG. Detection of the c-met proto-oncogene product in normal skin and tumours of melanocytic origin. J Pathol 1994; 174:191-9.
- Oeff MK, Seltmann H, Hiroi N, Nastos A, Makrantonaki E, Bornstein SR, et al. Differential regulation of Toll-like receptor and CD14 pathways by retinoids and corticosteroids in human sebocytes. Dermatology 2006; 213:266.
- Nagy I, Pivarcsi A, Kis K, Koreck A, Bodai L, McDowell A, et al. *Propionibacterium acnes* and lipopolysaccharide induce the expression of antibacterial peptides and proinflammatory cytokines/chemokines in human sebocytes. Microbes Infect 2006; 8:2195-205.